Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AFNT-211 |
Synonyms | |
Therapy Description |
AFNT-211 comprises autologous T-cells expressing a T-cell receptor targeting KRAS G12V in the context of HLA-A*11:010 and modified to enhance cell persistence, which potentially induces antitumor immune activity and cytotoxicity in KRAS G12V-expressing tumor cells (J Clin Oncol, 41, no. 16_suppl (2023) 2543). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AFNT-211 | AFNT211|AFNT 211 | AFNT-211 comprises autologous T-cells expressing a T-cell receptor targeting KRAS G12V in the context of HLA-A*11:010 and modified to enhance cell persistence, which potentially induces antitumor immune activity and cytotoxicity in KRAS G12V-expressing tumor cells (J Clin Oncol, 41, no. 16_suppl (2023) 2543). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06105021 | Phase Ib/II | AFNT-211 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | Recruiting | USA | 0 |